UTHSC In the Media

Memphis Man’s Inspiring Journey: From Police Officer to Dental Student

Published by World Today News
In the Media Icon

Memphis Man Trades Badge for‌ Dental Tools, Pursues New Career ⁤at UTHSC

Are Dentures Covered by Dental Insurance?

Published by The Podcast Park
In the Media Icon

Most dental insurance plans cover dentures at about 50% under major procedures, but limits, waiting periods, and annual maximums apply.

Are Dentures Covered by Dental Insurance?

Published by WLUS
In the Media Icon

Most dental insurance plans cover dentures at about 50% under major procedures, but limits, waiting periods, and annual maximums apply.

Rural health care in Tennessee is at a crossroads, but hope is on the horizon | Opinion

Published by The Tennessean
In the Media Icon

While rural health remains at a crossroads, there are programs that could provide rural Tennesseans access to high-quality health care.

Rural health care in Tennessee is at a crossroads, but hope is on the horizon | Opinion

Published by Leaf Chronicle
In the Media Icon

While rural health remains at a crossroads, there are programs that could provide rural Tennesseans access to high-quality health care.

Lumosa Therapeutics Announces Positive Results from Lt3001(Intravenous Odatroltide) Phase 2b Clinical Trial in Acute Ischemic Stroke

Published by Benzinga
In the Media Icon

Lumosa Therapeutics (Lumosa; 6535.TWO) today announced positive results from its Phase 2b clinical trial (LT3001-202) evaluating LT3001 (intravenous Odatroltide) in patients with acute ischemic stroke.

Lumosa Therapeutics Announces Positive Results from Lt3001(Intravenous Odatroltide) Phase 2b Clinical Trial in Acute Ischemic Stroke

Published by Yahoo! Finance
In the Media Icon

Lumosa Therapeutics (Lumosa; 6535.TWO) today announced positive results from its Phase 2b clinical trial (LT3001-202) evaluating LT3001 (intravenous Odatroltide) in patients with acute ischemic stroke.

Lumosa Therapeutics Announces Positive Results from Lt3001(Intravenous Odatroltide) Phase 2b Clinical Trial in Acute Ischemic Stroke

Published by PR Newswire
In the Media Icon

Lumosa Therapeutics (Lumosa; 6535.TWO) today announced positive results from its Phase 2b clinical trial (LT3001-202) evaluating LT3001 (intravenous Odatroltide) in patients with acute ischemic stroke.